Basilea Pharmaceutica AG : Resolutions of the Ordinary General Meeting of Shareholders of Basilea Pharmaceutica Ltd.

  Basilea Pharmaceutica AG : Resolutions of the Ordinary General Meeting of
                  Shareholders of Basilea Pharmaceutica Ltd.

Basilea Pharmaceutica AG / Resolutions of the Ordinary General Meeting of
Shareholders of Basilea Pharmaceutica Ltd. . Processed and transmitted by
Thomson Reuters ONE. The issuer is solely responsible for the content of this

Basel, Switzerland, April 9, 2013 - Basilea Pharmaceutica Ltd. (SIX: BSLN)
reported that shareholders approved all agenda items proposed at today's
Ordinary General Meeting of Shareholders for the financial year 2012. At the
meeting, 59.9 percent of Basilea's share capital was represented.

The shareholders approved the annual report, the financial statements and
consolidated financial statements for the business year 2012, and discharged
the members of the Board of Directors and Management. Shareholders also
approved carrying forward the accumulated deficit.

In addition, Dr. Martin Nicklasson was elected to the Board of Directors for a
term of three years. Basilea's Board of Directors now comprises seven
non-executive members: Dr. Martin Nicklasson, Mr. Hans-Beat Gürtler, Prof.
Daniel Lew, Dr. Thomas M. Rinderknecht, Mr. Domenico Scala, Mr. Steven D.
Skolsky and Dr. Thomas Werner. The Board of Directors elected Dr. Nicklasson
as Chairman of the Board and Domenico Scala as Vice-Chairman.

The shareholders re-elected PricewaterhouseCoopers AG, Basel, as Statutory
Auditors for the audit of the stand-alone and the consolidated financial
statements for the business year 2013.

Basilea's shareholders approved the proposal of HBM Healthcare Investments
(Cayman) Ltd., holding 24.97 percent of the company's shares, to distribute
CHF 5.00 per share corresponding to approximately CHF 48 million from capital
contribution reserves to shareholders. The payment will be made on June 21,
2013. The last trading day to participate in the distribution will be
April10, 2013. Starting from the ex-date of April 11, 2013, Basilea shares
will be traded without the right to participate in the distribution.

In his presentation to shareholders, Chief Executive Officer Ronald Scott
stated: "We achieved significant milestones in 2012 and successfully focused
on our core area of overcoming resistance in anti-infectives and oncology. The
company is uniquely positioned to potentially create significant value for our
shareholders as we move closer to the important milestones in the second half
of this year: the potential approval of our antibiotic ceftobiprole in Europe
as well as the first phase 3 results for our antifungal isavuconazole."

The Board and Management expressed their sincere thanks to the retiring Board
members Werner Henrich, Chairman since the company's inception, and Claude
Schreiner, Board Member since 2007, for their invaluable contributions.

Ronald Scott commented: "With his strategic vision, extensive experience in
deal-making and outstanding commitment, Werner Henrich has passionately worked
as our Chairman to build and grow the company for more than a decade. Claude
Schreiner's wide-ranging industry experience was instrumental in creating the
significant value of Toctino which we were able to achieve for shareholders
through our transaction with Stiefel/GSK last year."

With the addition of Dr. Nicklasson to the Board, the Board is convinced that
Basilea is well positioned to continue its path as one of the leading
biopharmaceutical companies addressing the growing medical need of drug

About Basilea

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed
on the SIX Swiss Exchange (SIX: BSLN). Through the fully integrated research
and development operations of its Swiss subsidiary Basilea Pharmaceutica
International Ltd., the Company focuses on innovative pharmaceutical products
in the therapeutic areas of bacterial infections, fungal infections and
oncology, targeting the medical challenge of rising resistance and
non-response to current treatment options.


This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
performance or achievements of Basilea Pharmaceutica Ltd. to be materially
different from any future results, performance or achievements expressed or
implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is
providing this communication as of this date and does not undertake to update
any forward-looking statements contained herein as a result of new
information, future events or otherwise.

For further information, please contact:

Media Relations             Investor Relations
Peer Nils Schröder, PhD     Barbara Zink, PhD, MBA
Head Public Relations &     Head Corporate Development
Corporate Communications
+41 61 606 1102             +41 61 606 1233

This press release can be downloaded from

Press release (PDF)


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: Basilea Pharmaceutica AG via Thomson Reuters ONE

--- End of Message ---

Basilea Pharmaceutica AG
Grenzacherstrasse 487
P.O Box Basel Switzerland

Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press spacebar to pause and continue. Press esc to stop.